Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Applied Therapeutics, Inc. - Common Stock (NQ: APLT )

0.6116 -0.0354 (-5.47%)
Streaming Delayed Price Updated: 12:52 PM EST, Feb 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Applied Therapeutics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Regulatory Setback For Applied Therapeutics' Lead Program, FDA Highlights Deficiencies In Clinical Application
FDA rejected Applied Therapeutics' Govorestat for galactosemia, citing NDA deficiencies. The company plans discussions for resubmission or appeal. 
Via Benzinga
Exposures Product Safety
Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Reports Third Quarter 2024 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference
From Applied Therapeutics
Via GlobeNewswire
Why Applied Therapeutics Stock Is Skyrocketing Today
Investors are cheering good news from the FDA. 
Via The Motley Fool
Steelcase Reports Weak Sales, Joins American Healthcare REIT And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Dow Jumps Over 100 Points; Fed Cuts Interest Rates By 0.5%
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Crude Oil Moves Lower; PowerFleet Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Russell 2000 Outpaces S&P 500 As Small Caps Anticipate Fed's Interest Rate Move
Small-cap stocks are surging ahead of the expected interest rate cut by the Federal Reserve, outperforming their larger-cap counterparts. However, potential for gains may be hindered by sluggish... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Applied Therapeutics Stock Soars As FDA Scraps Panel Meeting For Its Inherited Metabolic Disorder Drug
Applied Therapeutics stock rises as the FDA no longer requires an Advisory Committee meeting, keeping the Priority Review on track, with the PDUFA target date set for November 28. 
Via Benzinga
Exposures Product Safety
Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Applied Therapeutics to Participate in Upcoming Investor Conferences
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Reports Second Quarter 2024 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside
William Blair has initiated coverage on Applied Therapeutics highlighting its focus on rare diseases such as galactosemia, SORD deficiency, and diabetic cardiomyopathy. With govorestat (AT-007) poised... 
Via Benzinga
CrossFirst Bankshares Posts Q2 Earnings, Joins Owens & Minor, Reddit And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Applied Therapeutics Added to Russell 3000® Index
From Applied Therapeutics
Via GlobeNewswire
Top 4 Health Care Stocks That May Keep You Up At Night This Month
Via Benzinga
APLT Stock Earnings: Applied Therapeutics Meets EPS, Misses Revenue for Q1 2024
APLT stock results show that Applied Therapeutics met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Applied Therapeutics Reports First Quarter 2024 Financial Results
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
From Applied Therapeutics
Via GlobeNewswire
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
From Applied Therapeutics
Via GlobeNewswire
FDA Presses Delay Button For Applied Therapeutics' First Potential Marketed Drug For Rare Disease
FDA extends the review period for Applied Therapeutics' NDA for govorestat, targeting Classic Galactosemia treatment. The new action date is set for November 28, 2024. Applied Therapeutics anticipates... 
Via Benzinga
Exposures Product Safety
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash. Doma Holdings... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Oxford Industries Posts Weak Results, Joins Applied Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining by over 100 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
From Applied Therapeutics
Via GlobeNewswire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.